[{"id":"9de9a1df-22ec-481b-a91e-eefe5c853bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02791334","created_at":"2021-01-18T13:42:09.109Z","updated_at":"2024-07-02T16:34:59.807Z","phase":"Phase 1","brief_title":"A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT02791334","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 06/29/2016","start_date":" 06/29/2016","primary_txt":" Primary completion: 05/22/2020","primary_completion_date":" 05/22/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-31"}]